Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
2024 · The Lancet. Gastroenterology & hepatology · 43 citations
https://doi.org/10.1016/s2468-1253(24)00119-5